MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts - Concepedia

Concepedia

Publication | Open Access

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

DOI Full Paper Access

274

Citations

31

References

2011

Year

N.V. Rajeshkumar, Elizabeth De Oliveira, Niki A. Ottenhof, James Watters, David G. Brooks, Tim Demuth, Stuart D. Shumway, Shinji Mizuarai, Hiroshi Hirai, Anirban Maitra,

Clinical Cancer Research

Abstract

These results indicate that MK-1775 selectively synergizes with GEM to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

References

	Year	Citations

Page 1